---
title: "Tremfya (guselkumab) in plaque psoriasis: Guidelines questions"
description: "Guidelines questions on Tremfya (guselkumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: When do IPC guidelines support biologics like Tremfya regardless of BSA? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/guidelines"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab) in plaque psoriasis: Guidelines questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)

Questions that apply to every indication of Tremfya are on [Tremfya (guselkumab), all indications](https://www.evicenter.com/medical-information/tremfya).

## Guidelines

<a id="tremfya-ipc-guidelines"></a>

### When do IPC guidelines support biologics like Tremfya regardless of BSA?

> “IPC guidelines advocate that patients who have high-impact site involvement or who have failed topical therapies are eligible for systemic therapies, including biologics, regardless of BSA.”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#:~:text=IPC%20guidelines%20advocate%20that%20patients,including%20biologics%2C%20regardless%20of%20BSA.)

> “IPC=International Psoriasis Council.”

Source: [TREMFYA: Moderate Plaque PsO Low-BSA Data, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/data-low-bsa/#:~:text=IPC%3DInternational%20Psoriasis%20Council.)

Note: The International Psoriasis Council statement concerns systemic therapies, including biologics, as a class; the Tremfya page cites it beside the SPECTREM study in moderate plaque psoriasis.

## Related pages
- [Medical information: Tremfya (guselkumab): Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/access-and-coverage)
